Replimune REPL
NASDAQ REPL
$23.28 +1.02 (+4.58%)
At close: Nov 10, 2026 · 4:00 PM EST

Replimune (REPL) EBIT Margin (2017 - 2018)

Updated

Replimune's EBIT Margin came in at -1149.32% for fiscal Q3 2019 (quarter ended Dec 31, 2018), up 13638.18 percentage points from -14787.50% a year earlier but down 79.44 percentage points from the prior quarter.

Analysis

Replimune (REPL) EBIT Margin (2017 - 2018) Analysis & Trends

Over the trailing twelve months to Dec 31, 2018, Replimune reported EBIT Margin of -1672.30%.

  • The five-year range for quarterly EBIT Margin is -42560.00% (fiscal Q2 2018) to -1069.88% (fiscal Q2 2019).
  • Year-over-year, EBIT Margin has increased for three consecutive quarters.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 52.42%
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 24.35%
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 36.01%
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 30.89%
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 32.97%
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 20.57%
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 35.79%
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 41.71%
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 32.98%
10 Replimune 2.40 Bn 1.35 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 -1,149.32%
Sep 30, 2018 -1,069.88%
Jun 30, 2018 -2,589.87%
Dec 31, 2017 -14,787.50%
Sep 30, 2017 -42,560.00%
Jun 30, 2017 -10,586.67%
API Access

Replimune EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=REPL&period=max&api_key=YOUR_API_KEY